Physician profile
Dustin E Brown
NPI 1245681881
$2,105.23
in general payments reported to CMS, 2019-2025
19 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $146 · 2021: $219 · 2022: $226 · 2023: $367 · 2024: $218 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $654.11 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $330.95 | 2022-2025 | Biotrue One Day, Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $199.68 | 2019-2021 | |
| Alcon Vision LLC | $143.04 | 2021-2025 | Dailies Total1, Precision 1, Total30 |
| Sun Pharmaceutical Industries INC. | $123.61 | 2022-2025 | Cequa, Xelpros |
| Biotissue Holdings INC. | $103.58 | 2019-2025 | |
| Oyster Point Pharma, INC. | $99.15 | 2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $73.40 | 2020-2025 | |
| Maculogix, INC. | $65.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.99 | 2020-2022 | |
| Abbvie INC. | $48.33 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $46.28 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $44.56 | 2019 | |
| Kala Pharmaceuticals, INC. | $34.12 | 2021 | |
| Allergan, INC. | $23.08 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.56 | 2025 | Iyuzeh |
| Dompe US, INC. | $15.64 | 2025 | Oxervate |
| Topcon Healthcare, INC. | $14.17 | 2020 | |
| Quidel Corporation | $6.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.